Hierarchical therapeutic potential in the mesenchymal stem cell landscape.
Pearl JR., Marleau A., Pacheco DO., Mahant V., Mizer JC., Juarez P.
Narrative Review on Chronic Inflammation, Immune Modulation, published in J Transl Med (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Transl Med (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41398594
- PMCID
- PMC12706953
- DOI
- 10.1186/s12967-025-07391-5
Abstract (original English)
Mesenchymal stem cells (MSCs) are heterogeneous and versatile cells comprising distinct subpopulations with varying regenerative potential. MSCs have been widely explored in clinical research owing to their regenerative, tissue trophic, immune modulatory, and anti-inflammatory properties. Tissue-sourced autologous and allogeneic MSCs including those isolated from bone marrow, adipose tissue, and umbilical cord have been applied to clinical studies of a breadth of indications, providing ample evidence supporting the safety of MSC-based therapies. In some instances, clinical studies of MSCs have yielded variability in cell quality, potency, and therapeutic impact. Significantly, the Food and Drug Administration’s approval of the first MSC therapy, the allogeneic bone marrow MSC product Remestemcel-L-rknd (Ryoncil®), has fueled optimism for the clinical prospects of other investigational MSC products. The functional heterogeneity of MSCs has been demonstrated by studies of MSC subpopulations, often selected by surface marker expression or functional characteristics, that vary in clonogenicity, immunomodulatory potency, trophic factor production, and differentiation potential. While MSCs possess the ability to differentiate into mesodermal lineage cells, the potential for transdifferentiation of MSCs has been a matter of extensive scientific debate. There has been a strong impetus
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level ASystematic ReviewEurope PMC
Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention
Systematic Review on Osteoarthritis, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.
- 2026
Int J Nanomedicine1 citations - Level ASystematic ReviewEurope PMC
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Systematic Review on Chronic Inflammation, Immune Modulation, published in Front Oncol (2026) — summary generated from the PubMed abstract.
- 2026
Front Oncol - Level ASystematic ReviewEurope PMC
Trends in peripheral nerve injury research: a bibliometric analysis focused on molecular mechanisms
Systematic Review on Chronic Inflammation, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol